Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency

Similar Items

• Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
  by: Graham Walter, et al.
  Published: (2020-05-01)
• The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
  by: Bjorkander, J, et al.
  Published: (2000)
• In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
  by: Cozon GJN, et al.
  Published: (2018-03-01)
• Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
  by: Martin Adriana, et al.
  Published: (2012-11-01)
• Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients
  by: Susan E. Smith, et al.
  Published: (2023-06-01)